MOSCOW--(Marketwired - Jun 24, 2013) - Cromos Pharma, a full service regional contract research organization (CRO), announced today that it has begun operations in the Republic of Belarus. These operations are being conducted through Cromos Pharma's office in the city of Smolensk, Russia.
"When it comes to clinical research, Belarus has many attractive attributes," noted Dr. Vladimir Bogin, Chief Executive Officer of Cromos Pharma. "Belarus has a developed healthcare system, well-trained medical professionals with good knowledge of ICH/GCP and standards of care that are comparable to European medical practice," continued Dr. Bogin.
"Recent legislative concessions allow for a significant increase in the reimbursement of study teams. This signifies a substantial shift in state policy towards clinical research and has sparked a renewed interest in clinical trials by both medical centers and investigators," said Cromos Pharma's Managing Director, Andrey Tarakanov, MD. "The staff of our Smolensk office has considerable experience in all stages of clinical trial conduct in Belarus, and Cromos Pharma has a strong working relationship with local medical centers and investigators," he continued.
"Recent addition of Georgia and now of Belarus to its geographic footprint will allow Cromos Pharma to compete for even larger multi-center, international clinical trials," concluded Dr. Bogin.
Cromos Pharma has recently published a white paper which provides comprehensive updates on the Belarusian regulatory changes along with a brief overview of its healthcare system.
About Cromos Pharma, LLC
Cromos Pharma, LLC is a contract research organization (CRO) with operations in Russia, Ukraine and Eastern Europe and a business development office in the United States. The company provides a full spectrum of trial-related services which include regulatory approvals, medical writing, feasibility assessments, monitoring, project management and warehousing. Cromos Pharma, LLC is a privately owned company.
Cromos Pharma is pleased to share news about our latest project - an international double-blind placebo-controlled clinical trial of RPH-104 in acute ST-Elevation Myocardial Infarction (STEMI). The trial involving patients in the US and in Russia will investigate how a biologic RPH-104 developed by R-Pharm can reduce an acute inflammatory response after myocardial infarction and lead to improved outcomes for STEMI patients.
Throughout March we have been highlighting colorectal cancer, the amazing teams of researchers who are continuously fighting this disease, as well as the millions of patients and families who have been deeply affected by this silent killer. To close out this month of awareness-raising we want to introduce you to a real-life hero and colon cancer survivor - Arlene.
March is Colorectal Cancer Awareness Month. Colorectal cancer (CRC) is the third most common and second most deadly cancer worldwide according to 2020 figures from the Global Cancer Observatory.
Ukraine, the eight largest European country by population, is an attractive location for sponsors conducting clinical research for a number of key reasons. Cromos Pharma has been successfully managing clinical trials in Ukraine since 2006. This article looks at just some of the benefits of locating your next study here.
Cromos Pharma is continuously developing and looking to explore new territories when it comes to clinical research. In line with this spirit of discovery, we will be shortly commencing a new project in Uzbekistan supporting a study being conducted by the Swiss Tropical and Public Health Institute.
Cromos Pharma is delighted to be taking part in the upcoming DIA Europe conference (15 – 19 March 2021) and BIO-Europe Spring (22-25 March 2021).
February 11th is International Women and Girls in Science Day. A joint UNESCO and UN-Women initiative, it aims to promote the role of #WomenInScience and to challenge some of the barriers to girls pursuing a career in science.
Are you a sponsor seeking to conduct clinical trials in the European Union but do not have a registered office in the European Economic Area? If so, in order to comply with the European Union Clinical Trial Directive, you are required to work with a Legal Representative registered in an EEA country.
Each 4th February, #WorldCancerDay aims to raise awareness of the global personal, social and economic burden of cancer. World Cancer Day was established in Paris at the first World Cancer Summit in 2000.
As 2021 begins, many countries are grappling with a renewed surge of COVID-19 infections necessitating further public health restrictions putting more pressure on health systems, societies and global economies. The task of rolling out approved vaccines is increasingly urgent. Almost 16 million doses of COVID-19 vaccines have been administered to date in 37 countries worldwide according to data compiled by Bloomberg ( updated 7 Jan 2021).
Tuesday 1 December marked World AIDS Day 2020. Although throughout this year our focus has been on the coronavirus pandemic, World AIDS Day is an opportunity to reflect on another pandemic where a virus passed from animals to humans with devastating consequences. To date 77 million people worldwide have been infected with HIV. In spite of innovative new treatments 35 million people have died from the virus.
If you missed the live webinar “Where in the world should I locate my pivotal clinical trial?” you can now watch the recording by clicking here. The webinar hosted by the Society of Physician Entrepreneurs (SoPE) and Workforce Genetics features Cromos Pharma's CEO Vlad Bogin, M.D, FACP.